Fri, Nov 28, 2014, 11:22 AM EST - U.S. Markets close early today in 1 hr 38 mins for The day after Thanksgiving

Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • cphammer cphammer Oct 6, 2013 7:53 AM Flag

    A lot of distractors here, but what is the truth

    Afrezza works and works well. It has shown successful integration and proven success in artificial pancreas. Dr. Skylar a world renowned diabetologist has become outspoken that Afrezza could be used throughout the whole spectrum of diabetes. Although non inferior to injected insulin, Afrezza is superior in prandial glucose control. This is extremely important as the diabetes research community adhere to the benefits of glucose control rather than HbAc1 averages. Afrezza is the only ultra rapid acting insulin close to market approval. Afrezza , technosphere, and dreamboat delivery are backed by strong patent protection. The delivery system can be used for a wide spectrum of other drugs. Afrezza is represented by a powerhouse in Greenhill, experienced in large transactions and competent in independent advisement. Highly doubtful they would have taken the job if expectations were not reasonable or if no interest existed. Afrezza has secured financing well past approval timeline and results of trials to meet endpoint have been reviewed by an independent source that concur that FDA end points have been achieved. FDA meeting notes have been reviewed by Greenhill, Deerfield and potentially by partners. By the actions of those involved it appears Afrezza has cleared all FDA obstacles for approval. Mannkind has increased anticipated production lines by 1/3. Permits have been applied to expand facilities and machinery on order has arrived and is waiting installation. Filing is anticipated by mid October, and will not be affected by Govt Shutdown. EU filing will take place very shortly and interest from other countries to co-approve Afrezza with FDA or purchase Afrezza outright has been rumored by Management. Yes dilution of the stock has occurred over the last several years but more importantly the market for Afrezza has expanded several fold over the same period. Multiple BP's appear to be scrambling. Afrezza will change the way diabetes is treated and the way its monitored!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The fundamentals are fine, but the lingering problem is the 40 million 53-week warrants that were issued as part of a financing on October 20, 2012 and expire at the end of the month. These are not to be confused with the traded warrants which expire in 2016. There has been a relentless trading of various hedging strategies involving puts, calls,, shorting etc which have dominated trading since the August release of data. Of course, downside stock movements are only intensified. When the warraants are exercised, holders will have to pay the company $2.60 per share for the new stock, some approximately $80 million worth, and then the warrant exercisers will receive stock and can unwind the strategies. CEO/Chairman Mann also holds approximately the same amount and will exercise as well. (It's all in the original SEC iling for you to read.I think it's important for all long investors to recognize that this weakness is snot caused by a shift in the Afrezza story. I am an SEC registered person and required to state that this is my opinion only for information purposes only.

    • BUMP

      Sentiment: Strong Buy

    • Nice to read. Great facts and well written. Thank you! It is just a matter of time.

      Sentiment: Strong Buy

    • great post cp

      thanks

      Sentiment: Strong Buy

    • Mannkind has dedicated all of there efforts at the production level only. At this stage in the game, if they intended to go it alone, they would have to hire, train a marketing and sales force. They have not. With a 6 month approval timeline which may be potentially shortened, this would be suicide for a new product. My assumption is that partnership is in the bag. It benefits all parties to file with a strong BP and I believe Al has agreed. Agreements can be done to cover all future scenarios. As I have said before when all parties feel as if they have been screwed an agreement will take place. The distractors, shorts whatever you want to call them are here for one reason only. They stand to lose a ton of money if Afrezza is successful, either by a short position, or investment in other companies which stand to lose big time when Afrezza is approved. In this market as it pertains to future diabetes care, to the victor goes the spoils (Afezza), to the loser goes loss of market share and partnerships with inferior products!

      • 2 Replies to cphammer
      • This is probably one of the best reasons why they are not going to go it alone....which only leaves the alternatives.... buyout or partner.... this is a no brainer.....it will pop up on screen one day here soon...

        Sentiment: Strong Buy

      • An excellent summation of our current status CP. I have been here since well before the first CRL. I believe payday is finally just around the corner. Anyone who has waited this long can certainly wait a few more months for partnership and approval. While the current share price is unfortunate, it really won't matter in the long run. I wonder what other research is going on behind the scenes with the Technosphere technology? Patience is in order here. Thanks for your post.

        Paddler

    • I agree. Right now though, it is not reflected in what is going on with the PPS. For whatever reason, we are not seeing buyers, we are seeing sellers. This price drop from 8's is sad. See you in a few years, hopefully we are higher then. Until then, I lost my login and password to my trading account.

      Sentiment: Buy

 
MNKD
6.25-0.01(-0.16%)11:22 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.